Product NDC: | 0173-0716 |
Proprietary Name: | ADVAIR HFA |
Non Proprietary Name: | fluticasone propionate and salmeterol xinafoate |
Active Ingredient(s): | 115; 21 ug/1; ug/1 & nbsp; fluticasone propionate and salmeterol xinafoate |
Administration Route(s): | RESPIRATORY (INHALATION) |
Dosage Form(s): | AEROSOL, METERED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0173-0716 |
Labeler Name: | GlaxoSmithKline LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021254 |
Marketing Category: | NDA |
Start Marketing Date: | 20080929 |
Package NDC: | 0173-0716-20 |
Package Description: | 120 AEROSOL, METERED in 1 INHALER (0173-0716-20) |
NDC Code | 0173-0716-20 |
Proprietary Name | ADVAIR HFA |
Package Description | 120 AEROSOL, METERED in 1 INHALER (0173-0716-20) |
Product NDC | 0173-0716 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | fluticasone propionate and salmeterol xinafoate |
Dosage Form Name | AEROSOL, METERED |
Route Name | RESPIRATORY (INHALATION) |
Start Marketing Date | 20080929 |
Marketing Category Name | NDA |
Labeler Name | GlaxoSmithKline LLC |
Substance Name | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
Strength Number | 115; 21 |
Strength Unit | ug/1; ug/1 |
Pharmaceutical Classes | Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA],Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC] |